R&D channel feed

For­get TIG­IT: No­var­tis’ $1B bet on BeiGene’s ociper­limab ends af­ter com­peti­tors’ set­backs

Last year
Deals

Virid­i­an tar­gets Hori­zon's Te­pez­za with chron­ic thy­roid eye dis­ease da­ta, set­ting up the biotech for its sec­ond PhI­II

Last year

Mer­ck and Mod­er­na to start piv­otal can­cer vac­cine tri­al

Last year

FDA shifts how it pri­or­i­tizes which phar­ma sites to in­spect

Last year
Manufacturing

Aslan touts da­ta for com­peti­tor to Dupix­ent as it seeks new part­ners

Last year

Pen­ny stock biotech His­to­gen stops de­vel­op­ment pro­grams and con­sid­ers strate­gic al­ter­na­tives

Last year

Aus­tralia re­clas­si­fies psy­che­delics to fa­cil­i­tate med­ical use, as ad­vo­cates push for sim­i­lar move in US

Last year
Pharma

Mod­er­na pens deal with Chi­na to make mR­NA med­i­cines that 'will not be ex­port­ed'

Last year

'The more over­hype, the hard­er you fal­l': Schrödinger CEO warns on AI craze

Last year

De­fense De­part­ment en­lists Evotec to make new an­ti­body treat­ments for Mpox and oth­er pox­es

Last year
Deals

J&J will ad­vance pso­ri­a­sis drug li­censed from Pro­tag­o­nist af­ter fuller Phase IIb read­out

Last year
Pharma

As­traZeneca, Dai­ichi Sankyo claim PhI­II lung can­cer win for their next big ADC — but shares fall

Last year

FDA in­spec­tion at In­dia phar­ma at cen­ter of the cis­platin short­age cites mul­ti­ple qual­i­ty is­sues

Last year
Manufacturing

No­var­tis-led group de­vel­ops new class of an­tipar­a­sitic drug tar­get­ing dis­eases caused by try­panosomes

Last year
Discovery

Gen­fit, Ipsen tout piv­otal tri­al read­out for rare liv­er dis­ease, head to­ward FDA and EMA sub­mis­sions

Last year

Can­cer biotech In­ten­si­ty Ther­a­peu­tics looks to pull in $16M+ IPO

Last year
Financing

Madri­gal seeks ac­cel­er­at­ed ap­proval for ex­per­i­men­tal NASH treat­ment a week af­ter In­ter­cept re­jec­tion

Last year
FDA+

Cyteir to dis­solve as on­col­o­gy biotech scraps its fi­nal clin­i­cal at­tempt two years af­ter IPO

Last year
People

PTC Ther­a­peu­tics re­ports sec­ond tri­al flop for late-stage pro­gram

Last year

Liq­uidia and Unit­ed Ther­a­peu­tics could bring new lung in­di­ca­tion in­to le­gal saga

Last year

As it search­es for a new CEO, Il­lu­mi­na faces a high-stakes year of chal­lenges

Last year
People

BioX­cel stock craters af­ter dis­clo­sure of in­ves­ti­ga­tor's fal­si­fied safe­ty re­port in Alzheimer's study

Last year

Eiger Bio­Phar­ma­ceu­ti­cals to fo­cus on GLP-1 can­di­date, cut work­force by 25%

Last year
People

Aldeyra eyes po­ten­tial­ly piv­otal tri­al in re­tini­tis pig­men­tosa af­ter small open-la­bel read­out

Last year
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times